Results 11 to 20 of about 1,394 (181)

Transformation of HHV‐8‐negative idiopathic multicentric Castleman disease into diffuse large B‐cell lymphoma: A case report from Nepal [PDF]

Clinical Case Reports, 2023
Key Clinical Message Idiopathic Castleman disease transforming into Diffuse Large B‐cell Lymphoma has an aggressive course and can lead to mortality. Hence, early diagnosis and intervention are required. Abstract Idiopathic Castleman disease transforming
Ashwini Gupta, Ayush Anand, Salman Haidar Hussain, Raju Shah, Rajesh Ranjan, Viplaw Subedi, Aastha Baral, Akshat Mishra, Anju Pradhan, Soniya Dulal   +9 more
doaj   +2 more sources

Increased mTOR activation in idiopathic multicentric Castleman disease [PDF]

Blood, 2020
AbstractIdiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and life-threatening multiorgan dysfunction. Interleukin-6 (IL-6) inhibition effectively treats approximately one-third of patients.
Daniel J. Arenas, Katherine Floess, Dale Kobrin, Ruth-Anne Langan Pai, Maya Blanka Srkalovic, Mark-Avery Tamakloe, Rozena Rasheed, Jasira Ziglar, Johnson S. Khor, Sophia A. T. Parente, Sheila K. Pierson, Daniel Martínez, Gerald Wertheim, Taku Kambayashi, Joseph A. Baur, David T. Teachey, David C. Fajgenbaum   +16 more
openalex   +3 more sources

Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report [PDF]

Journal of Yeungnam Medical Science, 2022
Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disorder that may cause multiple organ damage. Castleman disease-associated diffuse parenchymal lung disease (DPLD) has not been well studied. A 32-year-old man was referred
Hyun-Je Kim, Young-Hoon Hong
doaj   +3 more sources

Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination

Journal of Cancer Research and Practice, 2023
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The preferred primary treatment for iMCD is siltuximab, an anti-interleukin-6 antibody (anti–IL-6).
Chien-Yu Ker, Hung-Wei Liu, Yu-Chieh Su, Pang-Yu Lai*   +3 more
doaj   +2 more sources

Idiopathic multicentric Castleman disease developing after a diagnosis of sarcoidosis: A case report and literature review. [PDF]

Respir Med Case Rep
A 72-year-old woman presented with an abnormal shadow on chest radiograph. She was histologically diagnosed with sarcoidosis 20 years previously, and prednisolone was initiated 8 years previously.
Muramatsu T, Kono M, Ishige M, Saito T, Higasa M, Nihashi F, Aono Y, Katsumata M, Miwa H, Miki Y, Misaki T, Otsuki Y, Hashimoto D, Enomoto N, Suda T, Nakamura H.   +15 more
europepmc   +2 more sources

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report [PDF]

Therapeutic Advances in Hematology, 2022
Human herpes virus-8 (HHV8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder sustained by pro-inflammatory cytokines, including interleukin-6 (IL-6).
Evan Lang, Brenda Sande, Samantha Brodkin, Frits van Rhee   +3 more
doaj   +2 more sources

Diagnostic and therapeutic challenges in hyaline-vascular idiopathic multicentric Castleman disease: A case report. [PDF]

J Int Med Res
The diagnosis of idiopathic multicentric Castleman disease typically requires serum interleukin-6 testing—often inaccessible in resource-limited settings.
Lu C, Ma X, Liu B, Wang J, Luo S, Luo Q.
europepmc   +2 more sources

A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report. [PDF]

Clin Case Rep, 2023
Key Clinical Message Idiopathic multicentric Castleman disease (iMCD) is challenging to diagnose due to clinical similarities with other conditions, such as Still's disease.
Strach M, Kuszmiersz P, Chmura Ł, Korkosz M.   +3 more
europepmc   +2 more sources

Leg‐type form of idiopathic multicentric Castleman disease associated with severe lower extremity chronic venous/lymphatic disease [PDF]

eJHaem, 2022
Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disease of unknown etiology. Deciphering mechanisms involved in CD pathogenesis may help improving patients’ care.
Thomas Ballul, Nabil Belfeki, Adèle deMasson, Véronique Meignin, Paul‐Louis Woerther, Antoine Martin, Elsa Poullot, Alain Wargnier, Jehane Fadlallah, Margaux Garzaro, Marion Malphettes, Claire Fieschi, Lucas Maisonobe, Hayat Bensekhri, Hélène Guillot, Rémi Bertinchamp, Marie Jachiet, Justine Poirot, Lionel Galicier, Eric Oksenhendler, David Boutboul   +20 more
doaj   +2 more sources

TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease

Bosnian Journal of Basic Medical Sciences, 2017
Castleman disease (CD) describes a group of three rare and poorly understood lymphoproliferative disorders that have heterogeneous clinical symptoms and common lymph node histopathological features. Unicentric CD (UCD) involves a single region of enlarged nodes.
Gordan Srkalović, Inga Marijanović, Maya Blanka Srkalovic, David C. Fajgenbaum   +3 more
openalex   +4 more sources